+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
P

Actively Recruiting

Researchers are evaluating HMBD-501, a HER3-targeted antibody-drug conjugate, in patients with advanced, relapsed, or refractory HER3-expressing solid tumors including melanoma, non-small cell lung cancer, and breast cancer. This Phase 12 trial aims to assess the safety, tolerability, how the drug moves in the body, and early signs of effectiveness. The study is sponsored by Hummingbird Bioscience and includes two parts a dose escalation phase followed by a dose expansion phase. During Phase 1, patients receive increasing doses of HMBD-501 by intravenous injection every three weeks to find the recommended dose for Phase 2. In Phase 2, patients receive this recommended dose to further evaluate the drugs preliminary clinical effects. The dose escalation helps identify the safest and most effective dose schedule for treating these advanced tumors. Participants will have regular visits for treatment, monitoring, and assessments including safety checks and blood tests to measure drug levels. The main outcomes include tracking any side effects during Phase 1 and measuring tumor responses in Phase 2 over about six months. Researchers will also study how the drug behaves in the body and monitor disease control and progression. Participants must follow the visit schedule and study procedures throughout the trial.

Age: 18Years +All GendersPhase 1Phase 2
7 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.

Age: 18Years +All GendersPhase 3
132 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-822, a drug being studied in healthy volunteers and participants with Metabolic Dysfunction-Associated Steatohepatitis MASH or presumed MASH. The study includes multiple parts involving different participant groups to assess various dosing regimens and formulations. The study is divided into six parts, enrolling approximately 168 participants total. Parts A, B, D, and F involve healthy volunteers receiving single or multiple ascending doses of INI-822 or placebo orally once daily. Parts C and E involve participants diagnosed with MASH or presumed MASH. Each part has distinct cohorts and durations ranging from 5 to 18 weeks, including screening. Some parts include crossover designs to assess food effects or tablet formulations. Participants will attend scheduled visits for screening, dosing, and follow-up assessments for up to 18 weeks depending on the study part. Researchers will monitor adverse events, clinical laboratory results, and pharmacokinetic parameters such as drug concentration over time. The study is randomized, double-blind, and placebo-controlled, with safety and laboratory abnormalities as primary outcomes. Participants will be closely observed throughout their assigned part of the trial.

Age: 18Years - 70YearsAll GendersPhase 1
11 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Navlimetostat BMS-986504 alone or together with Izalontamab Brengitecan in adults with advanced or metastatic Non-small Cell Lung Cancer NSCLC who have a specific genetic change called homozygous MTAP deletion or MTAP loss. Participants have experienced disease progression despite prior treatments. This is a Phase 2 randomized, open-label trial sponsored by Bristol-Myers Squibb. Participants receive either Navlimetostat alone at one of two doses or in combination with Izalontamab Brengitecan at one of two doses. The study is designed with sequential treatment groups and evaluates these treatments after prior therapies have failed. Dosing details are specified for each drug on designated days, and the study includes assessments to confirm genetic status before treatment. Throughout the study, participants undergo evaluations for tumor response using RECIST criteria, safety monitoring for adverse events including serious reactions up to 28 days after treatment ends, and quality of life assessments related to NSCLC symptoms. The primary outcome focuses on objective tumor response, with follow-up extending up to three years after the last dose. Participants health and laboratory tests are closely monitored during and after treatment to assess safety and efficacy.

Age: 18Years +All GendersPhase 2
67 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a new medicine called vepugratinib in adults with advanced or metastatic urothelial carcinoma, a type of bladder cancer with a specific FGFR3 genetic alteration. This phase 3 trial compares vepugratinib with a placebo when both are given alongside enfortumab vedotin and pembrolizumab. The study aims to understand if adding vepugratinib improves treatment outcomes and monitors adverse events over an extended period. Participants will receive oral vepugratinib or a matching placebo combined with intravenous enfortumab vedotin and pembrolizumab. The treatments are given in parallel groups, with some participants receiving the experimental drug and others the placebo, all alongside the standard IV therapies. The trial includes a safety lead-in phase and an extended treatment period, with study participation lasting up to approximately six years. During the trial, participants will undergo regular assessments including monitoring of treatment-related side effects, imaging to evaluate tumor response, blood tests to measure drug levels, and quality of life questionnaires. Researchers will track progression-free survival, overall survival, and response rates throughout the study and follow participants closely for safety and health status until study completion.

Age: 18Years +All GendersPhase 3
276 locations

1-10 of 26

1